A Study of Carmustine With and Without Ethanol in Subjects With Lymphoma
Phase 2
Recruiting
- Conditions
- LymphomaHodgkin LymphomaNon-Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2025-04-08
- Last Posted Date
- 2025-04-10
- Lead Sponsor
- VIVUS LLC
- Target Recruit Count
- 49
- Registration Number
- NCT06915246
- Locations
- ๐บ๐ธ
City of Hope Phoenix, Goodyear, Arizona, United States
๐บ๐ธCity of Hope National Medical Center, Duarte, California, United States
๐บ๐ธCity of Hope Atlanta, Newnan, Georgia, United States
A Study of VI-0521 on Ambulatory Blood Pressure (ABPM) in Overweight or Obese Subjects
- First Posted Date
- 2022-01-31
- Last Posted Date
- 2024-07-17
- Lead Sponsor
- VIVUS LLC
- Target Recruit Count
- 565
- Registration Number
- NCT05215418
- Locations
- ๐บ๐ธ
Clinical Site, Norfolk, Virginia, United States
๐บ๐ธClinical site, Salt Lake City, Utah, United States
A Phase IV Safety and Efficacy Study of VI-0521 in Adolescents With Obesity
Phase 4
Completed
- Conditions
- Adolescent ObesityObesity in AdolescenceAdolescent Overweight
- Interventions
- Drug: VI-0521 oral capsuleDrug: Placebo oral capsuleBehavioral: Lifestyle Modification
- First Posted Date
- 2019-04-22
- Last Posted Date
- 2022-09-10
- Lead Sponsor
- VIVUS LLC
- Target Recruit Count
- 223
- Registration Number
- NCT03922945
- Locations
- ๐บ๐ธ
Intend Research, LLC, Norman, Oklahoma, United States
A Pharmacokinetic Study Comparing VI-0521 With Placebo in Obese Adolescents
Phase 4
Completed
- Conditions
- Pediatric ObesityChildhood Obesity
- Interventions
- Drug: VI-0521 Mid DoseDrug: PlaceboDrug: VI-0521 Top Dose
- First Posted Date
- 2016-03-21
- Last Posted Date
- 2022-08-23
- Lead Sponsor
- VIVUS LLC
- Target Recruit Count
- 42
- Registration Number
- NCT02714062
- Locations
- ๐บ๐ธ
Research Facility, Charleston, South Carolina, United States
Effect of VI-0521 (Qsymiaยฎ) on Glomerular Filtration Rate (GFR) in Overweight or Obese Healthy Subjects
- First Posted Date
- 2014-09-01
- Last Posted Date
- 2017-11-07
- Lead Sponsor
- VIVUS LLC
- Target Recruit Count
- 51
- Registration Number
- NCT02229214
- Locations
- ๐บ๐ธ
Research Center, Lakewood, Colorado, United States
Safety Study Looking at the Effects of Stendra on Vision
- First Posted Date
- 2014-01-10
- Last Posted Date
- 2015-03-13
- Lead Sponsor
- VIVUS LLC
- Target Recruit Count
- 80
- Registration Number
- NCT02033200
- Locations
- ๐บ๐ธ
Celerion Inc, Tempe, Arizona, United States
Study Evaluating the Effects of Avanafil on Semen Parameters
- First Posted Date
- 2013-01-15
- Last Posted Date
- 2015-12-14
- Lead Sponsor
- VIVUS LLC
- Target Recruit Count
- 181
- Registration Number
- NCT01768676
- Locations
- ๐บ๐ธ
Research Facility, San Antonio, Texas, United States
Research Evaluating a PDE5 Inhibitor for Erectile Dysfunction
Phase 4
Completed
- Conditions
- Erectile Dysfunction
- Interventions
- First Posted Date
- 2012-10-03
- Last Posted Date
- 2014-10-27
- Lead Sponsor
- VIVUS LLC
- Target Recruit Count
- 440
- Registration Number
- NCT01698684
Study to Evaluate Hemodynamic Response to to a Sublingual Dose of Glyceryl Trinitrate in Subjects Receiving TA-1790, Sildenafil Citrate, and Placebo
Phase 1
Completed
- Conditions
- Erectile Dysfunction
- Interventions
- First Posted Date
- 2012-06-11
- Last Posted Date
- 2012-06-14
- Lead Sponsor
- VIVUS LLC
- Target Recruit Count
- 106
- Registration Number
- NCT01616485
- Locations
- ๐บ๐ธ
MDS Pharma Services, Phoenix, Arizona, United States
VI-1121 for the Treatment Alzheimer's Disease
- First Posted Date
- 2011-09-05
- Last Posted Date
- 2013-12-11
- Lead Sponsor
- VIVUS LLC
- Target Recruit Count
- 61
- Registration Number
- NCT01428362
ยฉ Copyright 2025. All Rights Reserved by MedPath